Isakov V A, Vodeĭko L P, Kabolova I V, Turkin V V
Ter Arkh. 2010;82(11):19-22.
To evaluate the tolerance and therapeutic effectiveness of 1.5% reamberine (RB) solution infusions in complex therapy for pneumonia-complicated pneumonia and acute respiratory diseases (ARD).
133 patients aged 18 to 60 years with pneumonia-complicated influenza and ARD were examined. The investigators measured the dynamic serum levels of metalloproteins (MP), such as transferrin, lactoferrin, and ceruloplasmin, and the activity of superoxide dismutase. They also studied the concentration of secondary lipid peroxidation products (malondialdehyde) by the so-called thiobarbituric acid test.
Dropwise intravenous RB infusions exerted a modifying effect on MP content, contributed to more pronounced stabilization of a serum antioxidant potential (versus olifen, vitamin E, and basic therapy) and to enhanced nonspecific protection, which was accompanied by a significant clinical improvement.
The study revealed the high clinical efficacy of 1.5% RB solution infusions (300 ml for 4-5 days) in the treatment of 74 patients with pneumonia-complicated influenza, stabilized serum antioxidant potential, and the body's enhanced nonspecific resistance.
评估1.5%雷美替胺（RB）溶液输注在肺炎合并流感及急性呼吸道疾病（ARD）综合治疗中的耐受性和治疗效果。
对133例年龄在18至60岁之间、患有肺炎合并流感及ARD的患者进行了检查。研究人员测量了金属蛋白（MP）的动态血清水平，如转铁蛋白、乳铁蛋白和铜蓝蛋白，以及超氧化物歧化酶的活性。他们还通过所谓的硫代巴比妥酸试验研究了继发性脂质过氧化产物（丙二醛）的浓度。
静脉滴注RB对MP含量产生调节作用，有助于更显著地稳定血清抗氧化潜能（与奥力芬、维生素E及基础治疗相比），并增强非特异性保护作用，同时伴有显著的临床改善。
该研究揭示了1.5%RB溶液输注（300毫升，持续4至5天）治疗74例肺炎合并流感患者具有较高的临床疗效，可稳定血清抗氧化潜能，并增强机体的非特异性抵抗力。
